MedTrace Logo

Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy

NCT05903833 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-05-11

No results posted yet for this study

Summary

Evaluation of efficacy and safety of pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulva cancer.

Conditions

  • Recurrent Vulvar Cancer
  • Persistent Vulvar Cancer
  • Metastatic Vulva Cancer
  • Locally Advanced Vulvar Cancer

Interventions

DRUG

Pembrolizumab

400 mg Q6W

DRUG

Lenvatinib

20 mg QD

Sponsors & Collaborators

  • AGO Research GmbH

    lead INDUSTRY

Principal Investigators

  • Linn Wölber, MD PhD · UKE Hamburg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-24
Primary Completion
2027-10-30
Completion
2029-10-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05903833 on ClinicalTrials.gov